Publicly-traded company Atara Biotherapeutics Inc. (NASDAQ:ATRA) had a closing price of $13.52 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $31.00, this means that the stock is underpriced by 56.39%. In the past 52 weeks the company’s stock price has moved within the range of $10.38 to $43.94.
This particular stock’s 5-day moving average is 12.57, its 20-day moving average is 12.42 and its 100-day moving average is 14.77. Atara Biotherapeutics Inc. (ATRA) currently has 48.43M shares outstanding, which means that its market capitalization is $654.77M.
The Details: Atara Biotherapeutics Inc. (ATRA) Financial Health
It is also smart to find out what a company’s Return on Assets is. This percentage tells us how well a company is making use of its net assets to generate a profit. The lower the percentage, the worse the company does with its available assets. At the moment, Atara Biotherapeutics Inc. Return on Assets is -77.80%.
What Does Wall Street Say about Company?
When considering a new stock purchase, a lot of investors find out how Wall Street analysts feel about the company before they buy in. You can do this by looking for the average analyst rating on the company’s stock. At the moment, the average analyst rating for ATRA is Overweight. Out of 9 total analysts who were surveyed, 1 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 2 rated it hold, and 6 rated it a Buy.
Three months ago, on the other hand, the average analyst rating for Atara Biotherapeutics Inc. (ATRA) was a Buy – from a survey of 10 analysts. Of the analysts who provided ratings, 2 rated the company a Hold, 0 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 8 rated it a Buy.
Understanding Profitability at Atara Biotherapeutics Inc. (ATRA)
Having a look at a company’s recent Earnings per Share (EPS) performance is a useful way of understanding its profitability. In the most recent financial results released by Atara Biotherapeutics Inc., for the quarter ending on 09/2019, the company posted EPS of -1.40. The average estimate of Wall Street analysts had projected -1.36.
Wall Street analysts, on average, are forecasting the company’s EPS to be -1.44, compared to -1.29 reported in the same quarter last year.